Guselkumab

Drug Profile

Guselkumab

Alternative Names: CNTO-1959

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator MorphoSys
  • Developer Janssen Biotech; MorphoSys
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Plaque psoriasis
  • Phase III Erythrodermic psoriasis; Palmoplantar pustulosis
  • Phase II Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 24 May 2017 Janssen Research & Development plans the Discover-1 phase III trial for Psoriatic arthritis (Treatment-experienced) in USA, Australia, Canada, Hungary, Malaysia, Poland, Russia and Taiwan (NCT03162796)
  • 10 May 2017 Phase-III clinical trials in Plaque psoriasis in Spain, Germany and Hungary (SC) (EudraCT2016-002995-29)
  • 27 Apr 2017 Janssen initiates enrolment in a phase III trial for Plaque psoriasis in USA (NCT03090100)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top